Show simple item record

dc.contributor.authorDe Vincentis, G
dc.contributor.authorGerritsen, W
dc.contributor.authorGschwend, JE
dc.contributor.authorHacker, M
dc.contributor.authorLewington, V
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorOya, M
dc.contributor.authorPacilio, M
dc.contributor.authorParker, C
dc.contributor.authorShore, N
dc.contributor.authorSartor, O
dc.contributor.authorTargeted Alpha Therapy Prostate Working Group
dc.date.accessioned2019-09-19T09:10:57Z
dc.date.issued2019-11
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2019, 30 (11), pp. 1728 - 1739
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3355
dc.identifier.eissn1569-8041
dc.identifier.doi10.1093/annonc/mdz270
dc.description.abstractAmongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. In this review, we discuss the history, progress, and future potential of TαT in the treatment of prostate cancer, including dosimetry-individualized treatment planning, combinations with small-molecule therapies, and conjugation to molecules directed against antigens expressed by prostate cancer cells, such as prostate-specific membrane antigen (PSMA) or components of the tumor microenvironment. A clinical proof of concept that TαT is efficacious in treating bone-metastatic castration-resistant prostate cancer has been demonstrated by radium-223 via improved overall survival and long-term safety/tolerability in the phase III ALSYMPCA trial. Dosimetry calculation and pharmacokinetic measurements of TαT provide the potential for optimization and individualized treatment planning for a precision medicine-based cancer management paradigm. The ability to combine TαTs with other agents, including chemotherapy, androgen receptor-targeting agents, DNA repair inhibitors, and immuno-oncology agents, is under investigation. Currently, TαTs that specifically target prostate cancer cells expressing PSMA represents a promising therapeutic approach. Both PSMA-targeted actinium-225 and thorium-227 conjugates are under investigation. The described clinical benefit, safety and tolerability of radium-223 and the recent progress in TαT trial development suggest that TαT occupies an important new role in prostate cancer treatment. Ongoing studies with newer dosimetry methods, PSMA targeting, and novel approaches to combination therapies should expand the utility of TαT in prostate cancer treatment.
dc.formatPrint
dc.format.extent1728 - 1739
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectTargeted Alpha Therapy Prostate Working Group
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectHeterocyclic Compounds, 1-Ring
dc.subjectProstate-Specific Antigen
dc.subjectDipeptides
dc.subjectRadiopharmaceuticals
dc.subjectRadioimmunotherapy
dc.subjectRadiotherapy Planning, Computer-Assisted
dc.subjectAlpha Particles
dc.subjectMale
dc.subjectClinical Trials, Phase III as Topic
dc.subjectTumor Microenvironment
dc.subjectPrecision Medicine
dc.subjectProgression-Free Survival
dc.titleAdvances in targeted alpha therapy for prostate cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdz270
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2019-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncology
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume30
pubs.embargo.termsNot known
dc.contributor.icrauthorParker, Chrisen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0